Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/BridgeBio seen as a strong Buy on Attruby's U.S. launch and Pfizer patent deals boosting market potential.
BBIO
$82.33
-$0.33 -0.41%

BridgeBio seen as a strong Buy on Attruby's U.S. launch and Pfizer patent deals boosting market potential.

Analyst Insights
29 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

BridgeBio Pharma remains a compelling Buy due to the strong U.S. launch of its drug Attruby and favorable market conditions after Pfizer's patent settlements. Attruby's peak annual sales are conservatively estimated at $2.2 billion, with potential up to $4 billion, supported by market exclusivity through mid-2031. The company’s late-stage pipeline drugs also offer potential for future blockbusters, enhancing long-term value. Despite risks from operating expenses, debt, and execution, Attruby's cash flow is expected to help reduce debt and maintain research and development momentum within two to three years.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App